Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital of North Norway | OTHER |
| St. Olavs Hospital | OTHER |
| Helse Stavanger HF | OTHER_GOV |
| The Hospital of Vestfold |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The prevalence of extended spectrum beta-lactamase (ESBL) producing bacteria found in urine sample cultures has been increasing over the past decades.
The study hypothesis is to assess the clinical and microbiological outcome of pivmecillinam treatment of ESBL producing E. coli and K. Pneumoni, as well as to observe the clinical and microbiological outcome of the same group of bacteria treated with other antiinfectious agents.
Samples are gathered in primary care setting.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ESBL producing E. coli bacteria | Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting. | ||
| Non-ESBL E.coli urinary tract infection | E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of days until symptomatic resolution | Number of days from the start of treatment that the patient feels completely free of urinary tract symptoms Number of days after start of antibiotic treatment with mecillinam when the patient feels free of symptoms from the urinary tract | Two weeks after finishing the primary antibiotic treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with ESBL producing bacteria detected in a urine sample taken two weeks after finishing initial treatment | Two weeks after end of initial treatment | |
| Number of patients who received a second treatment regime in the follow-up period | Number of patients who received a secondary antibiotic treatment to obtain clinical cure. |
Not provided
Inclusion Criteria:
- All patients were urinary sample taken in a primary care setting shows significant growth of ESBL producing E. coli.
Above age 16.
Exclusion Criteria:
- Sample from patients in hospital care or living in nursing home facilities. Inability to understand and sign information leaflet.
Not provided
Not provided
Not provided
The study population will be selected from all patients ages 16 and over who are diagnosed with an urinary tract infection where an ESBL producing bacteria (E. coli) is found. The urinary tract infection must be diagnosed and treated in a primary care setting.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Morten Lindbaek, Md PhD | University of Oslo | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vestre Viken Hospital Trust | Bærum | Norway | ||||
| University Hospital Akershus |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29982514 | Derived | Bollestad M, Grude N, Solhaug S, Raffelsberger N, Handal N, Nilsen HS, Romstad MR, Emmert A, Tveten Y, Soraas A, Jenum PA, Jenum S, Moller-Stray J, Weme ET, Lindbaek M, Simonsen GS; (the Norwegian ESBL UTI study group). Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. J Antimicrob Chemother. 2018 Sep 1;73(9):2503-2509. doi: 10.1093/jac/dky230. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| OTHER |
| Vestre Viken Hospital Trust | OTHER |
| University Hospital, Akershus | OTHER |
| Unilabs | UNKNOWN |
Not provided
Not provided
Not provided
Urinesamples
| 2 weeks after end of initial treatment |
| Lørenskog |
| Norway |
| Unilabs | Skien | Norway |
| Helse Stavanger HF | Stavanger | Norway |
| University Hospital of North Norway | Tromsø | Norway |
| St Olavs Hospital | Trondheim | Norway |
| Vestfold Hospital Trust | Tønsberg | Norway |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |